Research Explorer

Your browser does not support JavaScript or JavaScript is not enabled. Without JavaScript some functions of this webapplication may be disabled or cause error messages. To enable JavaScript, please consult the manual of your browser or contact your system administrator.

Researcher

Gwenn Waerlop

Awards & Distinctions

10 Results

2024

Safety and immunogenicity of a carbohydrate fatty acid monosulphate ester adjuvant combined with a low-dose quadrivalent split-virion inactivated influenza vaccine : a randomised, observer-blind, active-controlled, first-in-human, phase 1 study

Valentino D'OnofrioSharon PorrezBart JacobsAzhar AlhatemiFIEN DE BOEVERGwenn WaerlopEls MichelsFrancesca VanniAlessandro ManentiGeert Leroux-Roels et al.

A1 Journal Article in VACCINES

Safety and immunogenicity of the live-attenuated hRVFV-4s vaccine against Rift Valley fever in healthy adults : a dose-escalation, placebo-controlled, first-in-human, phase 1 randomised clinical trial

Isabel Leroux-RoelsChittappen Kandiyil PrajeethAmare AregayNiranjana NairGuus F RimmelzwaanAlbert D M E OsterhausSimone KardinahlSabrina PelzStephan BauerValentino D'Onofrio et al.

A1 Journal Article in LANCET INFECTIOUS DISEASES

2023

Harmonization of cellular immunoassays for the evaluation of influenza vaccine immunogenicity

Gwenn WaerlopIsabel Leroux-RoelsGeert Leroux-Roels

Immune responses in healthy adults elicited by a bivalent norovirus vaccine candidate composed of GI.4 and GII.4 VLPs without adjuvant

Gwenn WaerlopYorick JanssensBart JacobsFranziska JarczowskiAndré DiessnerGeert Leroux-RoelsVictor KlimyukIsabel Leroux-RoelsFrank Thieme

A1 Journal Article in FRONTIERS IN IMMUNOLOGY

Immunogenicity, safety, and preliminary efficacy evaluation of OVX836, a nucleoprotein-based universal influenza A vaccine candidate : a randomised, double-blind, placebo-controlled, phase 2a trial

Isabel Leroux-RoelsPaul WillemsGwenn WaerlopYorick JanssensJessika TourneurFIEN DE BOEVERJacques BruhwylerAzhar AlhatemiBart JacobsFlorence Nicolas et al.

A1 Journal Article in LANCET INFECTIOUS DISEASES

2022

A randomized, double-blind, placebo-controlled, dose-escalating phase I trial to evaluate safety and immunogenicity of a plant-produced, bivalent, recombinant norovirus-like particle vaccine

Isabel Leroux-RoelsCathy MaesJasper JoyeBart JacobsFranziska JarczowskiAndré DiessnerYorick JanssensGwenn WaerlopKirsi TamminenSuvi Heinimäki et al.

A1 Journal Article in FRONTIERS IN IMMUNOLOGY

Harmonization and qualification of an IFN-γ Enzyme-Linked ImmunoSpot assay (ELISPOT) to measure influenza-specific cell-mediated immunity within the FLUCOP consortium

Gwenn WaerlopGeert Leroux-RoelsTeresa LambeDuncan BellamyDonata MedagliniElena PettiniRebecca Jane CoxMai-Chi TrieuRichard DaviesGeir Bredholt et al.

A1 Journal Article in FRONTIERS IN IMMUNOLOGY

Harmonization and qualification of intracellular cytokine staining to measure influenza-specific CD4+ T cell immunity within the FLUCOP consortium

Sarah BegueGwenn WaerlopBruno SalaunMichel JanssensDuncan BellamyRebecca Jane CoxRichard DaviesElena GianchecchiDonata MedagliniEmanuele Montomoli et al.

A1 Journal Article in FRONTIERS IN IMMUNOLOGY

Randomized, double-blind, reference-controlled, phase 2a study evaluating the immunogenicity and safety of OVX836, a nucleoprotein-based influenza vaccine

Isabel Leroux-RoelsGwenn WaerlopJessika TourneurFIEN DE BOEVERCatherine MaesJacques BruhwylerDelphine Guyon-GellinPhilippe MorisJudith Del CampoPaul Willems et al.

A1 Journal Article in FRONTIERS IN IMMUNOLOGY

The role of cell-mediated immunity against influenza and its implications for vaccine evaluation

Yorick JanssensJasper JoyeGwenn WaerlopFrédéric ClementGeert Leroux-RoelsIsabel Leroux-Roels

A1 Journal Article in FRONTIERS IN IMMUNOLOGY